Simplified Measurement of Deoxyglucose Utilization Rate

Journal of Nuclear Medicine

Volumn 37, Issue 6, 1996, Pages 950-955

  Hunter, George J ^a   Hamberg, Leena M ^a   Alpert, Nathaniel M ^a   Choi, Noah C ^a   Fischman, Alan J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Diagnostic imaging.; Dose uptake ratio; Fluorine 18 FDG; Glucose metabolism; Lung cancer; PET

Indexed keywords

DEOXYGLUCOSE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GLUCOSE BLOOD LEVEL; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; SCINTISCANNING;

BLOOD GLUCOSE; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYGLUCOSE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; LUNG NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030160447     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
2. 18F] fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 1987;22:360-371.
3. Nolop KB, Rhodes CG, Brudin LH, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987;60:2682-2689.
4. Abe Y, Matsuzawa T, Fujiwara T, et al. Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: preliminary study of lung cancer. Int J Radiat Oncol Biol Phys 1990;19:1005-1010.
5. Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991;32:1655-1660.
6. 18F]-fluoro-2-deoxy-D-glucose. Radiology 1992;184:441-444.
7. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988;61:1776-1781.
8. Haberkorn U, Strauss LG, Reisser C, et al. Glucose uptake, perfusion and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry [see comments]. J Nucl Med 1991;32:1548-1555.
9. Bailet JW, Abemayor E, Jabour BA, Hawkins RA, Ho C, Ward PH. Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992;102:281-288.
10. Cher BC, Hoh C, Choi Y. Evaluation of primary head and neck tumor with PET-FDG [Abstract]. Clin Nucl Med 1990;15:758.
11. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67-citrate imaging for detection of lymphoma. J Nucl Med 1987;28:288-292.
12. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991;32:686-691.
13. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992;33:325-329.
14. 18F-fluorodeoxy-glucose. Clin Nucl Med 1992;17:361-363.
15. 18F]FDG uptake in primary cerebral lymphoma: a PET study J Comput Assist Tomogr 1988;12:47-48.
16. Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988;29:181-186.
17. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PKT. J Nucl Med 1991;32:1508-1512.
18. 18F ion and FDG [Abstract]. Clin Nucl Med 1990;15:763.
19. 18F]fluoro-D-glucose [Letter]. N Engl J Med 1991;324:200.
20. 18F]-fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-770.
21. 18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. J Urol 1991;145:279-283.
22. Francavilla TL, Miletich RS, DeMichele D, et al. Positron emission tomography of pituitary macroadenomas: hormone production and effects of therapies. Neurosurgery 1991;28:826-833.
23. De Souza B, Brunetti A, Fulham MJ, et al. Pituitary microadenomas: a PET study. Radiology 1990;177:39-44.
24. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of coloreclal tumors: PET evaluation. Radiology 1989;170:329-332.
25. 18F]fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med 1982;23:1133-1137.
26. Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992;33:333-339.
27. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18-fluorodeoxyglucose. J Nucl Med 1987;28:910-914.
28. Francavilla TL, Miletich RS, Di CG, Patronas NJ, Rizzoli HV, Wright DC. Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 1989;24:1-5.
29. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma: a predictor of prognosis. Cancer 1988;62:1074-1078.
30. Schlag P, Lehner B, Strauss LG, Georgi P, Herfarth C. Scar or recurrent rectal cancer. Positron emission tomography is more helpful for diagnosis than immunoscintigraphy. Arch Surg 1989;124:197-200.
31. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18-fluorodeoxyglucose. J Nucl Med 1988;29:1521-1525.
32. Minn H, Paul R. Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: frustration or future [Editorial]. Eur J Nucl Med 1992;19:921-924.
33. Hawkins RA, Choi Y, Huang SC, Messa C, Hoh CK, Phelps ME. Quantitating tumor glucose metabolism with FDG and PET [Editorial]. J Nucl Med 1992;33:339-344.
34. 18F]2-fluoro-2-deoxy-D-glucose: a comparison of different analytical methods. J Cereb Blood Flow Metab 1987;7:161-172.
35. Fischman AJ, Alpert NM. FDG-PET in oncology: there's more to it than looking at pictures [Editorial]. J Nucl Med 1993;34:6-11.
36. Graham MM, Lewellen TK. Positron emission tomography and its role in metabolic imaging. Mayo Clin Proc 1989;64:725-727.
37. Kim CK, Gupla NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction [see comments]. J Nucl Med 1994;35:164-167.
38. Langen KJ, Braun U, Kops RE, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993;34:355-359.
39. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med 1993;34:1-6.
40. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994;35:1308-1312.
41. 18F production. Int J Appl Radiat Isot 1984;35:599-602.
42. Hamacher K. Phase-transfer catalyzed synthesis of 4-S-β D-glucopyranosyl-2-thio-D-glucopyranose (thiocellobiose) and 2-S-β D-glucopyranosyl-2-thio-D-glucopyranose (thiosophorose). Carhohydr Res 1984;27:291-295.
43. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-238.
44. Rota KE, Herzog H, Schmid A, Holte S, Feinendegen LE. Performance characteristics of an eight-ring whole body PET scanner. J Comput Assist Tomogr 1990;14:437-445.
45. 18F]2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6:371-388.
46. Rhodes CG, Wise RJ, Gibbs JM, et al. In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 1983;14:614-626.
47. Guyton AC. Chapter 25. The body fluid compartments: extracellular and intracellular fluids: interstitial fluid and edema. In: Textbook of medical physiology, 8th ed. Philadelphia: W.B. Saunders; 1991:273-285.
48. Keyes JW, Harkness BA, Greven KM, Williams DW, Watson NE, McGuirt F. Pretherapy evaluation with PET of salivary tumors [Abstract]. Radiology 1993;147(suppl):189P.
49. Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995;36:788-793.
50. Lowe VJ, DeLong DM, Hoffman JM, Coleman RE. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 1995;36:883-887.
51. Gupta NC, Chandramouli B, Frank A, Dewan N, Scott W. PET FDG imaging for estimating probability of malignancy in solitary pulmonary nodules [Abstract]. Radiology 1993;147(suppl):189P.
52. Gupta N, Dewan N, Frank A, Mailliard J, Scott W. Presurgical evaluation of patients with suspected malignant pulmonary nodules using PET-FDG imaging [Abstract]. J Nucl Med 1993;34(suppl):20P.
53. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993;34:12-17.